A multi-award winning regional contract research organization (CRO)
Novotech has been instrumental in the success of over a thousand Phase I - IV clinical trials for biotechnology companies.
Solutions we offer
Where We operate
- North America
- 约1,800名调查员 参与了至少5项研究
Novotech has three customer facing offices
on both the East Coast and West Coast.
- Dr. John Moller
Chief Executive Officer, Novotech CRO
Novotech and PPC Group Announce Merger to Form Novotech Health Holdings
Combined company will create largest specialist biotech CRO platform in Asia to meet the rapidly growing demand for quality clinical
Novotech Finalist in Pharma Intelligence Citeline Awards 2020
Sydney, Australia – Novotech, the largest biotech specialist CRO in the Asia-Pacific region, is a finalist in the presti
Novotech CRO Ranked in Top 3 for Biotech IND Approvals in South Korea According to Ministry of Food and Drug Safety (MFDS)
Sydney - Australia – Novotech, the largest biotech specialist CRO in the Asia-Pacific region, is now ranked in the top t
Asia: Preferred Destination for Clinical Trials
Asia is the fastest-growing medicines market globally, with China currently the world’s second-largest market after the US, with medicines spending of $137 billion in 2018, up $40 billion from a decade earlier.
Australia: Preferred Destination for Early Phase Clinical Trials
The clinical trials process is complex. It requires substantial investment and skilled human re-sources, and involves risks, not least, the navigation of complex regulatory processes. To over-come these challenges, small biotechnology companies outsource their early phase clinical studies to contract research organizations (CROs). This white paper highlights research on why Australia continues to be a hub for early phase clinical trials.
Our Latest Reports
Regulatory requirements for clinical trials in Australia
With a streamlined regulatory environment, including no requirement for an IND, and the supportive R&D Government refund of up to 43.5% on clinical research spend, Australia has become a preferred destination for early phase clinical trials.
Accelerating Genetic Therapy Clinical Trials in Asia-Pacific
A growing number of biotechnology companies, both in the West and in Asia, are specializing in gene therapies and other regenerative treatments boosted by the approval of the first genetic therapy agent (tisagenlecleusel) by the FDA in 2017.
Accelerating Immunotherapy Clinical Trials in Asia-Pacific
Over 600 sites across Asia-Pacific have been involved in the clinical development of now approved IO drugs, and hundreds more are experienced in managing clinical trials with immunotherapies for both monotherapy and combination therapies.
Orphan drug trials accelerating in Asia Pacific
We have observed an unprecedented effort in the clinical development of Orphan drugs in the recent years. In fact, in 2018, the majority of new drugs approved by the FDA and EMA were Orphan medicines.
The objective of this report is to describe the Orphan drug development landscape and explain how the positioning of the Asia region has been evolving in the global picture.